Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea flag South Korea · Delayed Price · Currency is KRW
91,100
-600 (-0.65%)
Mar 27, 2026, 1:49 PM KST

KRX:185750 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,692,4041,586,4311,669,4041,488,3451,343,559
Other Revenue
--0---
1,692,4041,586,4311,669,4041,488,3451,343,559
Revenue Growth (YoY)
6.68%-4.97%12.16%10.78%3.11%
Cost of Revenue
1,166,0261,053,8201,007,203945,705847,741
Gross Profit
526,378532,611662,202542,639495,818
Selling, General & Admin
270,575267,793256,595237,936220,982
Research & Development
154,097143,914140,235176,325163,277
Amortization of Goodwill & Intangibles
3,8353,0802,1691,9261,794
Other Operating Expenses
12,13912,60511,69411,38712,206
Operating Expenses
445,810433,150415,602432,733401,060
Operating Income
80,56899,462246,599109,90694,759
Interest Expense
-6,699-8,319-9,271-6,847-4,030
Interest & Investment Income
7,25612,6916,0282,333759.37
Earnings From Equity Investments
--798.36-460.38-603.47
Currency Exchange Gain (Loss)
-2,0952,918-2,356-2,524-183.41
Other Non Operating Income (Expenses)
1,349-1,208-1,777838.33-10,128
EBT Excluding Unusual Items
80,378105,543240,021103,24680,573
Gain (Loss) on Sale of Investments
747.23-2,7641,465-2,223-98.87
Gain (Loss) on Sale of Assets
542.27154111.8854.05119.34
Asset Writedown
-15.58-923.8--3,912-
Pretax Income
81,652102,009241,59897,16580,594
Income Tax Expense
3,826-9,43327,99617,18738,237
Earnings From Continuing Operations
77,827111,442213,60279,97842,356
Minority Interest in Earnings
-318.2-2,369-1,081975.58363.91
Net Income
77,509109,073212,52180,95342,720
Net Income to Common
77,509109,073212,52180,95342,720
Net Income Growth
-28.94%-48.68%162.52%89.50%-53.38%
Shares Outstanding (Basic)
1313141314
Shares Outstanding (Diluted)
1313141314
Shares Change (YoY)
0.50%-5.20%3.79%-1.77%-0.73%
EPS (Basic)
5882.098234.4615210.376013.653117.38
EPS (Diluted)
5845.548234.0015210.376013.653117.38
EPS Growth
-29.01%-45.87%152.93%92.91%-53.03%
Free Cash Flow
-73,55825,815276,94222,836-35,339
Free Cash Flow Per Share
-5525.421948.9119821.041696.38-2578.75
Gross Margin
31.10%33.57%39.67%36.46%36.90%
Operating Margin
4.76%6.27%14.77%7.38%7.05%
Profit Margin
4.58%6.88%12.73%5.44%3.18%
Free Cash Flow Margin
-4.35%1.63%16.59%1.53%-2.63%
EBITDA
125,366139,234283,629143,504122,241
EBITDA Margin
7.41%8.78%16.99%9.64%9.10%
D&A For EBITDA
44,79839,77237,03033,59827,482
EBIT
80,56899,462246,599109,90694,759
EBIT Margin
4.76%6.27%14.77%7.38%7.05%
Effective Tax Rate
4.69%-11.59%17.69%47.45%
Advertising Expenses
75,73874,74069,70760,36451,329
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.